Cointime

RayzeBio

company

About

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

  • 101 - 250

Highlights

Total Funding Amount
$258M
Funding Rounds
3
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$105M
Industries
Biotechnology,Health Care,Medical Device,Pharmaceutical
Founded date
Jan 1, 2018
Number Of Employee
101 - 250
Operating Status
Active

RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$258M
RayzeBio has raised a total of $258M in funding over 2 rounds. Their latest funding was raised on Jun 15, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 15, 2021 Series C $108M 1 — — Detail
Dec 8, 2020 Series B $105M 1 — — Detail
Oct 14, 2020 Series A $45M 1 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
RayzeBio is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures — Series C
Cointime
เนื้อหา
บริษัท